

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
195														
196														
197														
198	Q17. Views on aspects of what is known so far about risdiplam													
199														
200		Very positive		Positive		Neither positive nor negative		Negative		Very negative		Don't know		Total
201		%	Nos	%	Nos	%	Nos	%	Nos	%	Nos	%	Nos	
202	Its safety profile	66	21	28	9	0	0	0	0	0	0	6	2	32
203	Its recorded adverse events profile	41	13	34	11	16	5	3	1	0	0	6	2	32
204	Its impact on motor milestones	63	20	28	9	3	1	0	0	0	0	6	2	32
205	Its impact on swallowing	53	17	31	10	6	2	0	0	0	0	9	3	32
206	Its impact on ability to communicate	47	15	28	9	9	3	0	0	0	0	16	5	32
207	Its impact on breathing ability	59	19	28	9	3	1	0	0	0	0	9	3	32
208	Its impact on frequency and duration of hospital stay	66	21	25	8	0	0	0	0	0	0	9	3	32
209	Its impact on stamina and fatigue	69	22	25	8	0	0	0	0	0	0	6	2	32
210	Its impact on quality of life	75	24	19	6	0	0	0	0	0	0	6	2	32
211	Its impact on female menstruation	22	7	3	1	25	8	9	3	0	0	41	13	32
212	Its impact on female fertility	13	4	3	1	31	10	9	3	0	0	44	14	32
213	Its impact on male fertility	2	3	3	1	34	11	13	4	0	0	41	13	32
214	See comments for responses											Total answering		32
215														
216	Q18. How acceptable risdiplam is as a whole													
217														
218		Totally acceptable								Totally unacceptable				
219		1		2		3		4		5				

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
250	Total answering		32											
251														
252														
253														
254	Q22. Any groups of people who have 5q SMA who should have priority access to risdiplam													
255														
256		%	Nos											
257	Yes	50	16											
258	No	25	8											
259	Don't know	25	8											
260	See comments for responses	38	12											
261	Total answering		32											
262														
263	Q23. Would they want their child to have access to NHS-funded risdiplam													
264														
265	Who is answering the question	Yes		No		Don't know / not sure		Total						
266		%	Nos	%	Nos	%	Nos							
267	I am a parent / guardian of the person who has / had	97	31	0	0	3	1	32						
268				Total answering		32								
269	Q24. Willing for comments to be used													
270														
271		Yes		No		Total								
272		%	Nos	%	Nos									
273	In submissions to NICE	97	31	3	1	32								
274	In any future submissions to the Scottish Medicines Consortium	94	30	6	2	32								
275	In any survey summaries published on SMA UK's website	94	30	6	2	32								

